NCT01597622 - BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115 | Biotech Hunter

Enrollment

142

Participants

Timeline

Start Date

June 11, 2012

Primary Completion Date

September 13, 2018

Study Completion Date

September 13, 2018

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG

Belimumab

10 mg/kg administered intravenously over 1 hour every 4 weeks

Trial Locations (27)

275-8580

GSK Investigational Site, Chiba

791-0295

GSK Investigational Site, Ehime

807-8555

GSK Investigational Site, Fukuoka

810-8563

GSK Investigational Site, Fukuoka

730-8619

GSK Investigational Site, Hiroshima

739-0002

GSK Investigational Site, Hiroshima

060-8604

GSK Investigational Site, Hokkaido

060-8648

GSK Investigational Site, Hokkaido

675-8545

GSK Investigational Site, Hyōgo

980-8574

GSK Investigational Site, Miyagi

857-1195

GSK Investigational Site, Nagasaki

710-8522

GSK Investigational Site, Okayama

901-0243

GSK Investigational Site, Okinawa

321-0293

GSK Investigational Site, Tochigi

104-8560

GSK Investigational Site, Tokyo

113-8431

GSK Investigational Site, Tokyo

160-8582

GSK Investigational Site, Tokyo

162-8655

GSK Investigational Site, Tokyo

602-715

GSK Investigational Site, Busan

Unknown

GSK Investigational Site, Busan

700-721

GSK Investigational Site, Daegu

400-711

GSK Investigational Site, Incheon

110-744

GSK Investigational Site, Seoul

133-792

GSK Investigational Site, Seoul

137-701

GSK Investigational Site, Seoul

150-713

GSK Investigational Site, Seoul

443-721

GSK Investigational Site, Suwon, Kyonggi-do